April Newsletter: Post-translational Regulation of Phosphatase and Tensin Homolog (PTEN)

Worldwide, more than 47 million people have been diagnosed with dementia, and the majority of these cases are caused by Alzheimer’s disease (AD); aside from the social burden, this neurodegenerative disease has an associated cost of 1.09% of the global gross domestic product. Severe cognitive impairment that leads to deficits in skilled movements, language, and recognition are pathophysiological hallmarks of AD. On a molecular level, neuropathological hallmarks include formation of beta-amyloid plaques and neurofibrillary tangles (NFTs) comprised of paired helical filaments of hyper-phosphorylated Tau proteins. This newsletter focuses on the mechanistic control of Tau by post-translational modifications (PTMs) and the development of novel AD therapeutics based on regulating the PTM status of Tau.

Click to read more


Also included in this newsletter:


  • Signal Seeker™ Kits and Pathway Tools, PTM Antibodies, Beads, and more.
  • Related Publications